ReviewThe Malaysian journal of medical sciences : MJMS2025
Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.
Review in The Malaysian journal of medical sciences : MJMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GLOBOCAN 2022 reported that breast cancer is a primary contributor to the incidence and mortality rates of cancer in women. The very high and low Human Development Index (HDI) tiers are the primary contributors to the highest incidence and mortality rates, respectively. This study aimed to provide a comprehensive landscape overview of trends, dynamics, and research hot spots on the application of tamoxifen in treating breast cancer over the past 50 years. We retrieved data from the Scopus database, spanning from 1973 to 2022. We utilised Microsoft Excel, Harzing's Publish or Perish, and VOSviewer to perform exhaustive analyses, including the publication trend, co-authorship, co-citation, co-occurrence of authors, organisations, countries, and keywords. A total of 3,721 publications fit the inclusion and exclusion criteria. Jordan VC was the most prominent author, making substantial contributions to the research topic. Erasmus MC was the most prolific organisation, while the Swiss Group for Clinical Cancer Research exhibited the most robust international collaboration. The United States and the United Kingdom consistently have the highest publication, TLS, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.